The Impact of New Drug Introduction on Drug Expenditure in Primary Health Care in Catalunya, Spain
| Autor: | Antoni Gilabert, José M Sotoca, María-Teresa Faixedas, Miguel Angel Torralba, Alba Prat, Corinne Zara |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Drug Utilization
Drug Consumption (economics) medicine.medical_specialty Pediatrics business.industry media_common.quotation_subject Public health Alternative medicine MEDLINE Retrospective cohort study Drug Prescriptions Spain Environmental health Humans Medicine Pharmacology (medical) Health Expenditures Medical prescription business Drug Approval Retrospective Studies media_common |
| Zdroj: | Annals of Pharmacotherapy. 39:177-182 |
| ISSN: | 1542-6270 1060-0280 |
| DOI: | 10.1345/aph.1e236 |
| Popis: | BACKGROUND:Introduction of new drugs is a dynamic process with a high impact on consumption and expenditure.OBJECTIVE:To analyze the prescription of new drugs and the associated costs in public health care in Catalunya, Spain, in 2002. The analysis also attempts a perspective of consumption in relation to the grade of therapeutic innovation of the new drugs.METHODS:Prescription data on all 86 new drugs licensed for use during 1998–2002 were analyzed, using the prescription item as unit and the cost.RESULTS:Prescription for new drugs in 2002 represented 4% of overall items prescribed and 13% of the cost. The mean new drug item cost was ¢39, while that of overall drugs was ¢13. New drug item increase over the previous year was 18.6% compared with 5.2% of the overall drugs, and the proportional cost increased by 25.7% and 9.9%, respectively. Ten new drugs represented 55.1% of the expenditure of this group. Antiasthmatic drugs represented 20.7% of the expenditure on new drugs, angiotensin-receptor blockers represented 18.6%, antiaggregants 9.7%, and nonsteroidal antiinflammatory drugs 6.9%. New drugs providing significant or modest therapeutic improvement represented 25.6% of overall new drug items and 32.3% of their cost.CONCLUSIONS:New drugs have a mean cost growth rate greater than that of existing drugs, with only a quarter of them offering advantages over existing drugs. More detailed evaluations of new medications are warranted before they can be recommended for general use so that a better distribution of the limited resources available may be made when prescribing drugs that are newly available through prescription. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|